Michael Celano joined Larimar Therapeutics in June 2020, as Chief Financial Officer (CFO). He brings over 30 years’ experience as a life science business leader with a broad skill set including capital raising, creative financing structures, investor relations, business development, manufacturing, tax planning, SEC compliance, and general business activities. Since transitioning from his public accounting career, Mr. Celano spent more than 15 years as a Chief Operating Officer (COO), CFO and board member with a series of high-growth life science companies. He is currently the Chairman of the Board of Directors (previously the audit committee chair) of OraSure Technologies, a molecular tools and diagnostic company. Mr. Celano was also on the Board of Performance Health, a private equity funded consumer healthcare products company sold to Patterson Medical in a dual track IPO / business sale process. Most recently, he was the COO and previously the CFO of Recro Pharma, a specialty pharmaceutical company. Mr. Celano also served as CFO of Kensey Nash until its acquisition by DSM. Previously, he served as CFO for BioRexis, which was sold to Pfizer. Before joining BioRexis, Mr. Celano spent 24 years in public accounting, where he co-chaired Andersen’s U.S. Life Sciences Practice. After leaving Andersen, he held similar leadership positions with KPMG. Mr. Celano received his BS in accounting from St Joseph’s University.